Hester Biosciences Limited (NSE:HESTERBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Hester Biosciences Limited (HESTERBIO)
Hester Biosciences Limited (NSE:HESTERBIO) has a market capitalization of $150.34 Million (Rs13.90 Billion) as of May 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #17631 globally and #914 in its home market, demonstrating a 9.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hester Biosciences Limited's stock price Rs1634.20 by its total outstanding shares 8506865 (8.51 Million). Analyse Hester Biosciences Limited (HESTERBIO) cash conversion ratio to see how efficiently the company converts income to cash.
Hester Biosciences Limited Market Cap History: 2015 to 2026
Hester Biosciences Limited's market capitalization history from 2015 to 2026. Data shows growth from $48.98 Million to $150.34 Million (9.48% CAGR).
Hester Biosciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hester Biosciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Hester Biosciences Limited's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.54x
Hester Biosciences Limited's market cap is 0.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $63.36 Million | $1.01 Billion | $188.83 Million | 0.06x | 0.34x |
| 2017 | $165.31 Million | $1.23 Billion | $234.48 Million | 0.13x | 0.71x |
| 2018 | $101.44 Million | $1.36 Billion | $256.21 Million | 0.07x | 0.40x |
| 2019 | $130.76 Million | $1.78 Billion | $415.67 Million | 0.07x | 0.31x |
| 2020 | $154.74 Million | $1.83 Billion | $291.71 Million | 0.08x | 0.53x |
| 2021 | $230.27 Million | $2.14 Billion | $344.30 Million | 0.11x | 0.67x |
| 2022 | $163.67 Million | $2.35 Billion | $393.20 Million | 0.07x | 0.42x |
| 2023 | $133.80 Million | $2.66 Billion | $266.27 Million | 0.05x | 0.50x |
| 2024 | $220.74 Million | $3.05 Billion | $188.89 Million | 0.07x | 1.17x |
| 2025 | $147.17 Million | $3.11 Billion | $274.88 Million | 0.05x | 0.54x |
Competitor Companies of HESTERBIO by Market Capitalization
Companies near Hester Biosciences Limited in the global market cap rankings as of May 4, 2026.
Key companies related to Hester Biosciences Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Hester Biosciences Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Hester Biosciences Limited's market cap moved from $48.98 Million to $ 150.34 Million, with a yearly change of 9.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs150.34 Million | +2.16% |
| 2025 | Rs147.17 Million | -33.33% |
| 2024 | Rs220.74 Million | +64.98% |
| 2023 | Rs133.80 Million | -18.25% |
| 2022 | Rs163.67 Million | -28.92% |
| 2021 | Rs230.27 Million | +48.81% |
| 2020 | Rs154.74 Million | +18.34% |
| 2019 | Rs130.76 Million | +28.91% |
| 2018 | Rs101.44 Million | -38.64% |
| 2017 | Rs165.31 Million | +160.92% |
| 2016 | Rs63.36 Million | +29.35% |
| 2015 | Rs48.98 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Hester Biosciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $150.34 Million USD |
| MoneyControl | $150.34 Million USD |
| MarketWatch | $150.34 Million USD |
| marketcap.company | $150.34 Million USD |
| Reuters | $150.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hester Biosciences Limited
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl… Read more